Impact of Marital Status on LVAD Mortality: A Single Center Experience Linda Njoroge MD, Mohamed Khayata MD, Kevin Charnas, Paul Bate, Madison Edge, James.

Slides:

Advertisements

Similar presentations

VALUE BASED CARE: The Role of INTERMACS INTERMACS 8 TH Annual Meeting James B, Young, M.D. Study Chair – INTERMACS May 5 th, 2014.

Advertisements

Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.

Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.

Estimating Benefit in Ambulatory Heart Failure Patients MedaMACS Progress Report 2014 Garrick C. Stewart, MD Brigham and Women’s Hospital.

Donor Utilization: Making Use of a Precious Resource in Cardiac Transplant Jason W. Smith, MD Assistant Professor of Surgery The University of Washington.

Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Advances In LVAD Patient Management

Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.

Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.

BWGHF Liège Heart transplantation 2008.

Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.

HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.

MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.

Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.

INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.

Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.

MCSRN Mechanical Circulatory Support Research Network

Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.

Differences in Pulsatile vs. Continuous-Flow Left Ventricular Assist Devices on Renal Function Antone Tatooles, MD; Laura A. Coyle, MSN, ACNP-BC; Colleen.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.

－ Higher SBP visit-to-visit variability (SBV) has been associated

The ALERT Trial.

These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

Jennifer A. Cowger, MD, Matthew A

Assist Devices for the Treatment of Cardiogenic Shock

Role of ECMO in Acute Cardiogenic Shock

Compassionate People World Class Care

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Effect of Acute Kidney Injury on Chronic Kidney Disease Progression and Proteinuria: Initial Results from a Pilot Study Horne K1, Scott R1, Packington.

Intermacs and the Scientific Registry of Transplant Recipients (SRTR)

Copyright © 2017 American Academy of Pediatrics.

Clinical outcome after SVR: Veterans Affairs

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients James K. Kirklin, MD, David C. Naftel,

Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart.

Liver only transplants in the UK Question 2: In terms of survival benefit.

Pediatric Transplantation Committee

More Than Survival: Futility

HEART-LUNG TRANSPLANTATION

INTERMACS So, with more detailed analyses from databases such as CTRD and ISHLT, there is an opportunity for identifying pts who, with their.

Pediatric Transplantation Committee

Patients´ perspective on palliative chemotherapy of colorectal and non - colorectal tumors # 581 M. Rehm 1, K. Trautmann 1, A. Rentsch 2, B. Hornemann.

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Crossing the Quality Chasm: Where are We and What’s Next?

Peng-jun Lu, MD, PhD1; Mei-Chun Hung, MPH, PhD1,2 ; Alissa C

HEART-LUNG TRANSPLANTATION

Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation? James K. Kirklin, MD, David C. Naftel,

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Proposal to Delay the HCC Exception Score Assignment

Kaplan-Meier curves for overall survival (OS) probability.

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9- Year Experience Jeffrey A. Morgan, MD, Pauline H. Go, MD, Linnea.

Arman Kilic, MD, Eric S. Weiss, MD, MPH, Jeremiah G

Linking Intermacs to the World:

Early Outcomes With Marginal Donor Hearts Compared With Left Ventricular Assist Device Support in Patients With Advanced Heart Failure Erin M. Schumer,

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Kaplan-Meier survival estimates for major cardiovascular events.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Alignment of Comparative Effectiveness through MedaMACS

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

HEART-LUNG TRANSPLANTATION

Presentation transcript:

Impact of Marital Status on LVAD Mortality: A Single Center Experience Linda Njoroge MD, Mohamed Khayata MD, Kevin Charnas, Paul Bate, Madison Edge, James White, Guilherme Oliveira MD, Mahazarin Ginwalla MD Linda Njoroge, MD Advanced Heart Failure and Transplantation Fellow 2017-2018 University Hospitals, Cleveland Medical Center Case Western Reserve University

Study Background LVADs offer both longer survival and improvements in QoL for carefully selected patients with inotrope-dependent heart failure. Family caregivers are particularly involved in LVAD therapy and are known to share feelings of anxiety, guilt and depression as well as have an increased sense of intimacy with the patients The 2013 ISHLT guidelines for MCS recommend assessment of the burden of the caregiver during the selection process - Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant. 2013;32:157–187.

Study Background This emphasizes the importance of social support in achieving optimal outcomes with LVAD therapy. We sought to investigate the effect of marital status on mortality outcomes in LVAD recipients at our center.

Methods: We collected retrospective data on BTT and DT LVAD patients implanted from 2007-2017 at our center. Institutional Review Board approval was obtained prior to accessing data from the INTERMACS database. A subset of 95 patients had complete follow-up data. Marital status was based on patient self-report survey that patients complete annually as part of their care

Methods: Cox regression model for time to death and marital status was performed. A Kaplan-Meier survival curve was generated for married vs non-married which included divorced, separated, widowed and domestic partner statuses.

Results: Overall survival in married LVAD recipients was 57% compared to 43% of non-married (p=0.45) There was greater survival observed survival in the first year after implantation. This benefit persisted 2 years post-LVAD implantation.

Results:

Conclusion: This study suggests a trend towards improved survival in married compared to non-married patients following the index hospitalization. This may be related to consistency of social support in married patients. This support is conferred in terms of response to LVAD alarms, driveline management including dressing changes, recognition of adverse events and presence during outpatient follow up. Close monitoring of non-married patients should be considered.